glp 1 fda compounding ban issued 25 warning letters to telehealth companies for false and misleading Managing Compounded GLP-1 Medications: A

In 2022, the FDA placed BPC-157 on its list of bulk drug substances that may not be used in compounding under Section 503A, though enforcement actions have varied by jurisdiction [5]

There are blood tests and other things medicine can do to help us adapt better without reaching for (yet another) cup of caffeine

Not sure who to use

Stanislaw Burzynski develops treatments using antineoplastons, which he claims cancer patients lack, potentially leading to recovery

For the pancreas, there is a small potential risk of pancreatitis

In preclinical heart-failure models, elamipretide improved left ventricular function and attenuated remodeling